PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type...
Oct 2, 2025, 7:00 AM EDT - 2 days ago
Sep 26, 2025, 4:01 PM EDT - 8 days ago
Sep 25, 2025, 9:46 AM EDT - 9 days ago
Sep 24, 2025, 10:51 PM EDT - 9 days ago
Sep 24, 2025, 4:21 PM EDT - 10 days ago
Sep 24, 2025, 4:16 PM EDT - 10 days ago
Aug 7, 2025, 8:00 AM EDT - 2 months ago
Jul 30, 2025, 5:41 PM EDT - 2 months ago
Jul 29, 2025, 10:33 AM EDT - 2 months ago
Jul 23, 2025, 11:22 AM EDT - 2 months ago
Jun 23, 2025, 9:00 AM EDT - 3 months ago
Jun 16, 2025, 10:39 AM EDT - 3 months ago
Jun 10, 2025, 10:44 AM EDT - 4 months ago
May 29, 2025, 9:19 AM EDT - 4 months ago
May 28, 2025, 6:21 PM EDT - 4 months ago
May 28, 2025, 4:05 PM EDT - 4 months ago
May 20, 2025, 7:00 AM EDT - 4 months ago
May 8, 2025, 8:00 AM EDT - 5 months ago
Apr 2, 2025, 4:05 PM EDT - 6 months ago
Mar 31, 2025, 4:05 PM EDT - 6 months ago
Mar 10, 2025, 4:05 PM EDT - 7 months ago
Mar 4, 2025, 1:41 PM EST - 7 months ago
Mar 4, 2025, 8:05 AM EST - 7 months ago
Mar 4, 2025, 8:00 AM EST - 7 months ago
Feb 24, 2025, 7:30 AM EST - 7 months ago
Feb 24, 2025, 7:00 AM EST - 7 months ago
Jan 29, 2025, 4:05 PM EST - 8 months ago